Real-World Data on Inotuzumab Ozogamicin for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A GRELAL-Chile Study

Espinoza, Marcela; Rojas-Vallejos, Jorge; Rodriguez, Nicolas; Guerrero, Gonzalo; Lopez, Miguel; Aranguiz, Natalia; Conte, Guillermo; Samaniego, Francisco; Quinteros, Nicolas; Astete, Daniel; Carcamo, Lucas; Flores, Constanza; Huerta, Ximena; Chandia, Mauricio; Valenzuela, Jorge; Navarrete, Marcelo; Flores, Yorman; Larrazabal, Agatha; Zapata, Edgar; Jerez, Joaquin

doi:https://doi.org/10.1002/cam4.71230

Real-World Data on Inotuzumab Ozogamicin for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A GRELAL-Chile Study

Espinoza, Marcela

[1];

Rojas-Vallejos, Jorge

[2];

Rodriguez, Nicolas

[3];

Guerrero, Gonzalo

[4];

Lopez, Miguel

[5];

Aranguiz, Natalia

[5];

Conte, Guillermo

[3];

Samaniego, Francisco

[3];

Quinteros, Nicolas

[3];

Astete, Daniel

[3];

Carcamo, Lucas

[6];

Flores, Constanza

[7];

Huerta, Ximena

[8];

Chandia, Mauricio

[9];

Valenzuela, Jorge

[10];

Navarrete, Marcelo

[11];

Flores, Yorman

[12];

Larrazabal, Agatha

[13];

Zapata, Edgar

[13];

Jerez, Joaquin

[13]

¹
Clinica Davila
²
Universidad Andres Bello
³
Universidad de Chile
⁴
Clin RedSalud Vitacura
⁵
Clinica Alemana
⁶
Hosp Gustavo Fricke
⁷
Hosp San Juan de Dios La Serena
⁸
Hosp Carlos Van Buren
⁹
Hosp Guillermo Gran Benavente
¹⁰
Universidad de Concepcion
¹¹
Escuela de Medicina
¹²
Pontificia Universidad Catolica de Chile
¹³
Universidad de los Andes - Chile

DOI

https://doi.org/10.1002/cam4.71230

Date Issued

2025-09-12

Type

Artículo

Journal

Cancer Medicine

ISSN

2045-7634

Volume

14

Links

https://arca.umag.cl/handle/123456789/15831

Background Inotuzumab Ozogamicin (InO) has shown efficacy in relapsed/refractory acute lymphoblastic leukemia (R/R ALL), but evidence from Latin America is scarce. We evaluated the outcomes of Chilean patients treated with InO in public and private health centers. Methods We retrospectively analyzed 35 patients with R/R ALL (median age 33 years; 54% male). Twenty percent had BCR::ABL-positive ALL, 78% expressed CD22, and 91% expressed CD19. Response rates, measurable residual disease (MRD), survival outcomes, and treatment-related toxicities were assessed. Multivariate analyses explored prognostic factors. Results Complete remission or remission with incomplete recovery (CR/CRi) was achieved in 74% of patients. Among those evaluated, 82% reached MRD < 0.01%. Patients undergoing allogeneic hematopoietic stem cell transplantation (Allo-HSCT) after InO had superior overall survival (OS) compared with those who did not (24.2 vs. 5.2 months). Median progression-free survival (PFS) was 6.9 months and median OS was 8.8 months. Sinusoidal obstruction syndrome occurred in 14% of patients but was generally mild. Multivariate analysis identified comorbidities and high blast counts as adverse prognostic factors, whereas MRD negativity and subsequent Allo-HSCT were associated with improved outcomes. Conclusions InO demonstrated high remission and MRD negativity rates in Chilean patients with R/R ALL, with OS and PFS comparable to existing research. Although SOS incidence was higher, it was generally mild. Achieving MRD negativity and proceeding to Allo-HSCT provided the greatest survival benefit. Study limitations include short follow-up and limited data.

acute lymphoblastic l...

inotuzumab ozogamicin...

sinusoidal obstructio...

Name

Cancer_Medicine_-_2025_-_Espinoza_-_Real‐World_Data_on_Inotuzumab_Ozogamicin_for_Adult_Patients_With_Relapsed_Refractory.pdf

Type

Main Article

Size

949.81 KB

Format

Adobe PDF

Checksum

(MD5):72b7930f9fa834d37902022247f44c81

Attribution 4.0 International